Quark Pharmaceuticals, Inc. Announces First Systemic SiRNA Dosing In Humans

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). [click link for full article]

More: continued here

Filed under: Clinical Trials on November 20th, 2007